Back to today’s briefing

Story perspectives

Promising Duchenne Treatment KER-065 Advances to Phase 2 Trial

4/3/2025

35 3

Summary

Story summary

KER-065 shows promise as a treatment for Duchenne muscular dystrophy (DMD), boasting a strong safety record in its Phase 1 trial with no serious side effects reported. Keros Therapeutics is gearing up to engage with regulators, aiming to kick off a Phase 2 trial in early 2026, with hopes of enhancing muscle mass and strength by targeting myostatin and activin A.

1 of 1

Story summary

KER-065 shows promise as a treatment for Duchenne muscular dystrophy (DMD), boasting a strong safety record in its Phase 1 trial with no serious side effects reported. Keros Therapeutics is gearing up to engage with regulators, aiming to kick off a Phase 2 trial in early 2026, with hopes of enhancing muscle mass and strength by targeting myostatin and activin A.